# NCT02954874 (NCT02954874)

> Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02954874
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Breast Carcinoma In Situ; Invasive Breast Carcinoma; Stage I Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma
- Interventions: Biospecimen Collection; Laboratory Biomarker Analysis; Patient Observation; Pembrolizumab; Quality-of-Life Assessment; Questionnaire Administration; Radiation Therapy
- Enrollment: 1195
- Primary outcome: Invasive disease-free survival (IDFS)
- Primary outcome: Severity of fatigue
- Primary outcome: Physical function

## Commentary we found

- YouTube: 4
- Podcasts: 1
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02954874